TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Pregnancies That did not Result in Fetal Loss, Intrauterine Transfusion (IUT), Hydrops Fetalis, or Neonatal Death
Endpoint domain: Mortality/survival
Primary endpoint: Total standing time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants who screen and enroll among those approached
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to reach study enrollment target
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Study retention rate at 12 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Behavioral outcome
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Number of participants experiencing dose limiting toxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawal Symptoms Assessment Using the Physician Withdrawal Checklist (PWC-20)
Endpoint domain: Adverse events/effects
Primary endpoint: Residual disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minimal residual disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 1 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed get up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional independence measurement for children (WEEFIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to First Occurrence of a Relapse Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in side effect number
Endpoint domain: Adverse events/effects
Primary endpoint: Mean inspection completeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: refractoriness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of responders determined by aesthetic improvement of the midface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate/ concentration of renal function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HBV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Satisfaction (including drug adherence) to TAF switch therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of intra-hepatic triglyceride content (IHTG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oncologists' communication behaviors - RE subscale (reassurance and emotional support)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of blood calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FEV1 (% of the predicted value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HER2 status identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response to anti-HER2 directed therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change of the third lumbar vertebrae skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Clinical Test of Sensory Interaction in Balance (CTSIB-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilirubin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: GGT value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chair sit and reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the NNC0487-0111 plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grades III and IV thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum level of superoxide dismutase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta of cT1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-expiratory lung impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Screening test of primary aldosteronism (Supine standing test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Confirmatory test of primary aldosteronism (Captopril test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: clinical hand recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hand pressure strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early identification of HPV-driven OPC lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients that achieve minimal residual disease (MRD) negativity in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrent CSDH requiring reoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tremor duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyskinesia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditioned Pain Modulation at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditioned Pain Modulation at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST/HR Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful weaning from High Flow Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma nitrite and nitrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Short-Chain Fatty Acid (SCFA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in lymphocyte activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in cytokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in serum inflammatory cytokine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in diversity of immune-modulating and butyrate-producing gut bacteria in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in concentration of Immunoglobulin A in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of vital physiological signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of vital physiological signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of vital physiological signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline concentration of Serum anti-Mullerian hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical pregnancy rate (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Autism Spectrum Rating Scales (ASRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life in Autism Part A (QoLA-A)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hours of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total brain small vessel disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceived harmfulness and avoidance of lifting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of use of modern contraceptives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lumbar pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Questionnaire 1 change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability Questionnaire 2 change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Participants who have Adopted CF-CS at Baseline
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent of Participants who have Adopted CF-CS at Month 12
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of symptomatic malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of anatomical variants of dural sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient preference and treatment comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of normal and abnormal ultrasound examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate on the first attempt of PIVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment Late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Distensibility of the pylorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: midsagittal tongue cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tongue width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of all-grade vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Validity of the Italian Elderly Mobility Scale (EMS-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3209590
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of LY3209590
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT Variability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants achieving Intended dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Axial Length (AL) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spherical Equivalent of Cycloplegic Autorefraction (SECAR) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious and significant ocular adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Participant Reported Nasal Congestion Score Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Endoscopic Nasal Polyp Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Gut Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Gut Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery 15 (QoR15) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: experimental associative memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve (AUC) for discrimination between invasive and in situ melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: urinary incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year overall recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in number of days of opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Infection events of grade 3 or more
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Prolonged Nightly Fasting (PNF) compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiome and microbial metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent ischemic stroke within treated territory
Endpoint domain: Mortality/survival
Primary endpoint: Intracerebral hemorrhage (ICH)
Endpoint domain: Mortality/survival
Primary endpoint: Neurological death in treated territory
Endpoint domain: Mortality/survival
Primary endpoint: Rate of miscarriage per trimester
Endpoint domain: Mortality/survival
Primary endpoint: Postpartum Bonding according to the Maternal-to-Infant Bonding Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Achieving Response in Reduction of Proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological measurements acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of fezolinetant in plasma: AUC24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of ES259564 in plasma: AUC24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time up and go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day good clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10-Meter Walk Test at Self-selected Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10-Meter Walk Test at Fast Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Assessment - Lower Extremity (FMA-LE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Ashworth Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to typical Alzheimer's Disease (AD)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of fracture nonunion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of implant-related failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence and severity of Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of steps from a mobile application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking speed from a mobile application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking distance from a mobile application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of transfusions and/or intravenous iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of kidney dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of individuals receiving a screening CT order and scan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Child Maltreatment Status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Exposure to Intimate Partner Violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Report of Intimate Partner Violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DLR Intervention Enrollment Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DLR Intervention Retention Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete molecular response (CMR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician knowledge in screening for skin cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence, severity, seriousness and relatedness to treatment of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of grade 2 or higher adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with =0.5 log10 reduction in HIV-1 plasma viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: biodistribution measured by SUVmean and SUVmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BASDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the remaining muscular layer (TRM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-Cell Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: First Phase Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Second Phase Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of completed therapies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participants' adherence to the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Uterine Arteries Pulsatility Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Malawi Developmental Assessment Tool global z-score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: marginal bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amounts of sun spray applied to the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MyChart Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Successful delivery of the GPX Embolic Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful occlusion of flow beyond the target vessel embolization site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of correct monosyllabic word scores in quiet at 50 dB SPL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adaptive sentence in noise scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary imaging abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in VAS scale for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety STAI-6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hepatic venous pressure gradient measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic resonance elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver biopsy major findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Self-reported pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Self-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life